Literature DB >> 23695596

Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation.

Chris Wiebe1, Peter Nickerson.   

Abstract

PURPOSE OF REVIEW: To summarize the evidence supporting the negative impact of de novo donor-specific antibodies (dnDSA) in renal transplantation and to describe the natural history associated with the development of dnDSA. RECENT
FINDINGS: Recent studies have increased our appreciation of the risk factors that predispose to dnDSA while illuminating how these risk factors may relate to the pathophysiology underlying its development. In addition, details regarding the natural history of dnDSA are now available in the context of the different clinical pathologic phenotypes that occur in the patients in whom it develops. Common pitfalls in defining and monitoring dnDSA, when understood, may provide some explanation for the heterogeneity in published studies.
SUMMARY: Recognizing that dnDSA is a major cause of late graft loss, and, more importantly, is detectable in many cases long before dysfunction or graft loss occurs, identifies an opportunity to intervene and change the outcome for the patient.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23695596     DOI: 10.1097/MOT.0b013e3283626149

Source DB:  PubMed          Journal:  Curr Opin Organ Transplant        ISSN: 1087-2418            Impact factor:   2.640


  19 in total

1.  Induction Therapy in Renal Transplantation: Why? What Agent? What Dose? We May Never Know.

Authors:  Alexander C Wiseman
Journal:  Clin J Am Soc Nephrol       Date:  2015-05-15       Impact factor: 8.237

2.  AST Cutting Edge of Transplantation 2013 Meeting Report: a comprehensive look at B cells and antibodies in transplantation.

Authors:  M Mengel; A Chong; D M Rothstein; E Zorn; J S Maltzman
Journal:  Am J Transplant       Date:  2014-01-24       Impact factor: 8.086

3.  From Pipe Dream to Donor-Specific PC Elimination: Novel Ways to Target Alloantibodies.

Authors:  Anita S Chong
Journal:  Transplantation       Date:  2016-11       Impact factor: 4.939

Review 4.  Utility of HLA Antibody Testing in Kidney Transplantation.

Authors:  Ana Konvalinka; Kathryn Tinckam
Journal:  J Am Soc Nephrol       Date:  2015-03-24       Impact factor: 10.121

5.  Predicting kidney transplant outcomes with partial knowledge of HLA mismatch.

Authors:  Charles F Manski; Anat R Tambur; Michael Gmeiner
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-23       Impact factor: 11.205

6.  Transplantation: Complementing donor-specific antibody testing.

Authors:  Kathryn J Tinckam; Peter S Heeger
Journal:  Nat Rev Nephrol       Date:  2013-11-05       Impact factor: 28.314

7.  T cell depletion increases humoral response by favoring T follicular helper cells expansion.

Authors:  Rodrigo Benedetti Gassen; Thiago J Borges; María José Pérez-Sáez; Hengcheng Zhang; Ayman Al Jurdi; Laura Llinàs-Mallol; Bruno Aoyama; Maurício Lima; Julio Pascual; Peter T Sage; Naoka Murakami; Leonardo V Riella
Journal:  Am J Transplant       Date:  2022-04-15       Impact factor: 9.369

Review 8.  HLA sensitisation: can it be prevented?

Authors:  Lesley Rees; Jon Jin Kim
Journal:  Pediatr Nephrol       Date:  2014-07-26       Impact factor: 3.714

9.  Torque Teno Virus Load-Inverse Association With Antibody-Mediated Rejection After Kidney Transplantation.

Authors:  Martin Schiemann; Elisabeth Puchhammer-Stöckl; Farsad Eskandary; Philip Kohlbeck; Susanne Rasoul-Rockenschaub; Andreas Heilos; Nicolas Kozakowski; Irene Görzer; Željko Kikić; Harald Herkner; Georg A Böhmig; Gregor Bond
Journal:  Transplantation       Date:  2017-02       Impact factor: 4.939

10.  Posttransplant allosensitization in low immunological risk kidney and kidney-pancreas graft recipients.

Authors:  Jorge Malheiro; Sandra Tafulo; Leonídio Dias; La Salete Martins; Isabel Fonseca; Manuela Almeida; Sofia Pedroso; Fátima Freitas; Idalina Beirão; António Castro Henriques; António Cabrita
Journal:  Biomed Res Int       Date:  2014-04-15       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.